Upfront Briefing
Generate Biomedicines priced its IPO at $400M — a clean read-through on biotech risk appetite, with AI-drug-discovery names very much in the chat.
On the pipeline front, Lilly’s oral GLP-1 drug orforglipron posted a head-to-head efficacy edge vs Novo’s Rybelsus, while ataiBeckley’s MDMA Phase 2a showed a social-anxiety signal (with durability/dosing questions still invited to the next meeting).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,908.9 |
(0.5%) |
+0.9% |
| Nasdaq 100 |
25,034.4 |
(1.2%) |
(0.9%) |
| Russell 2000 |
2,677.3 |
+0.5% |
+7.9% |
| Healthcare (XLV) |
157.4 |
(0.3%) |
+1.7% |
| Biotech (XBI) |
127.7 |
(0.5%) |
+4.7% |
| Nasdaq Biotech (NBI) |
5,987.7 |
(0.7%) |
+4.9% |
| Clinical Trials (BBC) |
42.7 |
(0.1%) |
+10.9% |
|
-
Risk-off was led by mega-cap AI: Nvidia’s post-earnings drop cooled the AI bid, dragging the Nasdaq complex while small caps held up.
-
Biotech traded like “long duration” again (XBI/NBI down with growth), but the YTD tape is still constructive as financing/IPO windows reopen.
- Market data: U.S. close Thu 26-Feb-2026.
The Big 3
|
1
|
Generate Biomedicines IPO priced at $400M
|
-
Generate Biomedicines priced its initial public offering at $400 million, signaling continued activity in the biotech IPO market, particularly for AI-drug-discovery companies.
-
Why it matters:
A $400M IPO at-range is a genuine “window test”: it signals public buyers will fund platform stories again (not just late-stage), and it sets a valuation/aftermarket comp for the next wave of AI-bio issuers lining up behind it.
-
Source:
BioPharma Dive
-
More:
PR
|
|
2
|
Lilly's GLP-1 pill outperforms Novo's Rybelsus in trial
|
-
Eli Lilly's oral GLP-1 drug, orforglipron, showed superior efficacy compared to Novo Nordisk's Rybelsus in a head-to-head clinical trial.
-
Why it matters:
Head-to-head efficacy is the share-shaper for orals — but tolerability is the adoption governor. If Lilly can manage discontinuations and secure broad labeling, orforglipron becomes a credible “oral switch” vector that pressures Novo’s oral franchise and reframes peak-sales assumptions for the pill segment.
-
Source:
BioPharma Dive
|
|
3
|
AtaiBeckley MDMA Phase 2a shows social anxiety signal
|
-
AtaiBeckley's MDMA Phase 2a trial showed a signal for social anxiety, though questions remain regarding durability and dosing for future trials.
-
Why it matters:
Psychedelics remain a “data + durability” trade: early signal can re-open capital for the complex, but the investable question is whether effect size persists and scales cleanly into registrational design (dose, durability, functional endpoints) in a still-skeptical regulatory backdrop.
-
Source:
BioCentury
-
More:
Endpoints
|
Everything Else that broke
- FDA probes complaints against CBER Director Vinay Prasad. — Endpoints
- Boehringer wins FDA accelerated approval for lung cancer drug. — Endpoints
- Viatris to lay off 10% of staff, reports Indian factory fire. — Endpoints
- Bristol Myers ADC shows breast cancer results. — BioPharma Dive
- DOJ urges Supreme Court to undo Hikma 'skinny label' case. — Endpoints
- Senate hearing raises concerns on FDA rare disease drug process. — Endpoints
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
-
Boehringer Ingelheim licenses a preclinical oral immunology program from Sitryx; deal includes upfront/near-term payments and >$500M in potential milestones plus tiered royalties. —
BI
-
Werewolf Therapeutics says it is exploring strategic alternatives (including potential sale/merger). —
PR
VC / Private Financings
-
BreezeBio raises $60M Series B (post-GenEdit rebrand) and pivots platform into internal pipeline — co-led by Yuanta Investment and DSC Investment, joined by SV Investment, Kiwoom Investment, and Dayli Partners. —
BioCentury
IPOs / Follow-Ons
Things that make you go hmmm ...
Source: GS and X (@drrichjlaw).
Academic Corner
- Preventive vaccines for hereditary cancer syndromes. — Nature Medicine
- The therapeutic potential of orphan adhesion G-protein-coupled receptors. — Nature RDD
- Dose-finding and optimization in drug development for rare diseases. — Nature RDD
- Fertility Preservation in People With Cancer. — JAMA Online First
|
